Skip to main content

Table 3 Subgroup analysis of global morphological and functional measures based derived from CMR

From: Patients who do not fulfill criteria for hypertrophic cardiomyopathy but have unexplained giant T-wave inversion: a cardiovascular magnetic resonance mid-term follow-up study

 

Group 1 (G1)

Group 2 (G2)

p for  Baseline

p for follow-up

p for change

Baseline (n = 16)

Follow-up (n = 16)

Change /years

Baseline (n = 55)

Follow-up (n = 55)

Change /yr

LA dimension (mm)

32.4 ± 5.2

33.5 ± 4.6

0.4 ± 0.8

31.9 ± 4.2

32.2 ± 4.4

0.2 ± 0.5

0.679

0.319

0.211

LVEDD (mm)

47.8 ± 3.8

46.6 ± 5.1

− 0.5 ± 0.8

47.8 ± 3.7

47.5 ± 3.7

− 0.2 ± 0.6

0.991

0.474

0.101

LVEF (%)

67.5 ± 6.4

69.5 ± 5. 9

0.7 ± 0.9

67.4 ± 6.4

67.4 ± 6.4

0.0 ± 0.8

0.938

0.243

0.002

LVEDVI (ml/m2)

56.3 ± 14.3

52.9 ± 17.1

− 1.3 ± 2.4

56.4 ± 11.1

55.0 ± 10.9

− 0.9 ± 1.3

0.968

0.569

0.542

LVESVI (ml/m2)

18.3 ± 5.8

16.1 ± 5.0

− 0.8 ± 0.9

18.6 ± 5.8

18.1 ± 5.6

− 0.3 ± 0.4

0.851

0.188

0.039

LV CI (L/min/m2)

2.50 ± 0.66

2.50 ± 0.83

− 0.01 ± 0.14

2.47 ± 0.55

2.39 ± 0.55

− 0.04 ± 0.09

0.726

0.550

0.334

LV mass(g)

97.1 ± 26.1

106.5 ± 29.5

3.3 ± 3.1

95.2 ± 30.2

96.9 ± 30.9

1.2 ± 2.4

0.822

0.276

0.005

LV mass index(g/m2)

52.8 ± 13.8

56.8 ± 14.6

1.4 ± 1.9

51.4 ± 15.2

51.7 ± 15.5

0.2 ± 1.2

0.750

0.245

0.026

apA (°)

76.3 ± 17.2

72.7 ± 21.5

− 1.5 ± 2.7

89.2 ± 11.5

87.9 ± 11.6

− 0.7 ± 2.0

0.001

 < 0.001

 < 0.001

LGE positive(n)

0

3

0

1

LGE volume(g)

0

3.50,3.27,2.60

0

2.63

LGE percent (%)

0

4.4,6.2, 4.4

0

3.8,

  1. P < 0.05 is considered significant. LAD left atrium dimension, LV  left ventricular, LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction, LVEDVI left ventricular stroke volume index, LVESVI left ventricle end-systole volume index, CI cardiac index, LGE late gadolinium enhancement